Albendazole: a new single dose anthelmintic. Study in 1455 patients

Area of Science:

• Medical Research
• Parasitology
• Clinical Pharmacology

Background:

• Intestinal parasitic infections are a significant global health concern, particularly in tropical and subtropical regions.
• Albendazole is a benzimidazole anthelmintic widely used for treating various helminthic infections.

Purpose of the Study:

• To evaluate the efficacy and safety of albendazole in a large, multi-center open trial.
• To assess albendazole's effectiveness against specific intestinal nematodes including roundworms, pinworms, hookworms, and whipworms.

Main Methods:

• An open-label trial involving 1455 patients across France, West-Africa, Martinique, and China.
• Patients received a single oral dose of albendazole.
• Efficacy was assessed by fecal examination (Kato test, concentration technique, coproculture for Necator americanus) before and after treatment.
• Clinical side effects and hematological/clinical chemistry values were monitored.

Main Results:

• Albendazole demonstrated high efficacy: 100% in enterobiasis, 89% in ascariasis, 88% in ancylostomiasis (Necator americanus), and 70% in trichuriasis.
• The drug was well-tolerated, with no significant adverse reactions or changes in hematological or clinical chemistry parameters.
• Only 6% of patients reported minor, transient side effects.

Conclusions:

• Albendazole is a highly effective and safe anthelmintic agent for treating common intestinal nematode infections.
• Its broad-spectrum activity and favorable safety profile support its continued use in public health programs for soil-transmitted helminths.